And as I said, in terms of resistant population, their physician population is much, much bigger than any acute space. In terms of ibrutinib and Rezurock, for example, these drugs are used perhaps in the third line setting. As far as we can tell, ibrutinib usage is declining and Rezurock uses third line after Jakafi. But in terms of axatilimab’s opportunity, we think it’s a great opportunity. In fact, even the success of Rezurock in the third-line setting, I think, bodes well for the success of axatilimab in that setting. And I think it’s a uniquely different drug. And when we talk to people who treat bone marrow transplant docs who treat GVHD, they’re looking forward to this product very much. In terms of tafa — in terms of tafa-len combination.
It’s a great combination in the second-line setting. You’ve seen the results in terms of overall response rate, complete response rates of 40%, a non-chemotherapy option in the second-line setting. I think the issue there is really that the second line and the whole diffuse large B-cell lymphoma marketplace has changed dramatically with increased competition, particularly with the CAR-T therapies moving into the second line setting, it becomes a challenging place for us to break through, but it’s absolutely a very good product that has — can have complete responses with long durations of response and we’re continuing to try to expand the use of this drug because we think patients will really benefit from it. And it’s really just the competition and the increasing competition in that particular setting in the second line plus setting, that’s somewhat of a challenge.
Operator: Next question is coming from Allison Bratzel from Piper Sandler.
Allison Bratzel : One for me on Opzelura. I know a determinant of the ultimate size of the vitiligo opportunity is going to be activation of patients who aren’t currently seeking treatment. I know it’s clearly early days in the launch, but just wondering if there’s anything you can say about how patient activation is tracking against your expectations? Or is this not really expected to be a driver until vitiligo specific DTC is underway? And then just a separate question on the other hem/onc franchise, just that 2023 guidance range seems to imply somewhat limited growth compared to ’22. So just could you expand on the growth areas for that franchise for the year? And any sort of pushes and pulls you considered in the 2023 guidance range?
Barry Flannelly : Okay. So I’ll start, and then I’ll hand off to Christiana, I guess. So in terms of patient activation for vitiligo, I think it’s happening already. We haven’t started linear and nonlinear TV commercials, direct-to-consumer TV commercials for vitiligo yet. That will start very soon. But patients are being activated. There’s direct-to-consumer activities going on online, on social media, on Internet searches. We work very closely with the vitiligo patient advocacy community. We work with healthcare professionals and even do live programming between healthcare professionals and patients. So that is occurring now, and it will continue to a much greater degree in the future. I think you can see by our presentations, there’s lots of excitement for patients who have gotten very good experience using the drug and are proud to share that.
So that helps a great deal in informing patients who may actually benefit from this drug. And in terms of guidance, perhaps, I’ll hand it over to Christiana.
Christiana Stamoulis : So in terms of the guidance for other hem/onc, the guidance range that we have provided is $215 million to $225 million with primary driver being Minjuvi, of the increase, yes.
Operator: Our final question today is coming from Matt Phipps from William Blair.
